Navigation Links
Spark Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference
Date:12/20/2013

PHILADELPHIA, Dec. 20, 2013 /PRNewswire/ -- Spark Therapeutics, a fully integrated, late-stage gene therapy company, announced today that President and Chief Executive Officer Jeffrey D. Marrazzo will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference. Marrazzo's presentation will highlight the company's progress in developing potentially curative, one-time gene therapies for the treatment of inherited blindness and hemophilia, and provide an overview of Spark's expertise and capabilities in the clinical development of adeno-associated virus (AAV) vectors.  The presentation will take place at 1:30 PM PT on Tuesday, January 14, 2014 in the Elizabethan C room at the Westin St. Francis in San Francisco, California.

About Spark Therapeutics                                                                                           

Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases. The founding team includes scientists who led the movement to develop gene therapy as a new treatment paradigm, establishing clinical proof of concept in the eye and liver and contributing key insights to the field that have resulted in a resurgence of industry interest in gene-based medicines. Our robust pipeline includes a Phase 3 program in RPE65 blindness and a Phase 1/2 program in hemophilia B, as well as preclinical programs to address neurodegenerative diseases and other retinal degenerative diseases and hematologic disorders. Spark has rights to a proprietary manufacturing platform that has an unparalleled track record of success in supporting clinical studies across diverse therapeutic areas and routes of administration. The company's expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark's team while at The Children's Hospital of Philadelphia Center for Cellular and Molecular Therapeutics. To learn more visit www.sparktx.com.

For information contact:
Jess Rowlands
Feinstein Kean Healthcare
202-729-4089
jessica.rowlands@fkhealth.com


'/>"/>
SOURCE Spark Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Snoring Therapy Awarded The Prestigious Spark Award
2. Kalyspo Awarded Best of Ann Arbor SPARK Boot Camp
3. Next Generation Sequencing Bioinformatics Heats up: Nearing $1000 Genome Sparks Soaring Data Output
4. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
6. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
9. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
10. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016  Lannett Company, Inc. (NYSE: LCI ) ... Markets 2016 Prescription for Success Healthcare Conference on December 14, 2016 ... New York City . In addition, the ... Guggenheim Securities 4 th Annual Boston Healthcare Conference taking place ... ...
(Date:12/6/2016)... , Dec. 6, 2016 Radioisotopes are ... Radioisotopes are produced either by using nuclear research reactor ... the form of alpha, beta or gamma when changed ... are used in Nuclear medicine, specifically in medical diagnostics. ... diagnostic information about a human body,s functioning. Radiotherapy is ...
(Date:12/6/2016)... Dec. 6, 2016 Human Vaccines Market: ... region wise and country wise analysis of the ... manufacturers of human vaccines products, raw material suppliers, ... enter the market. The report provides qualitative ... market. Qualitative analysis comprises market dynamics, trends, product ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... “Tomorrow Trump Goes To Washington”: ... greatness back to the presidency and to America. “Tomorrow Trump Goes To Washington” is ... much as she can for this country. , Nancy attributes her patriotic nature to ...
(Date:12/7/2016)... ... 2016 , ... “Fred Rides a Train” allows readers to tag along on ... Rides a Train” is the creation of published author, Janet Morrison, who has been ... Michigan. The "Fred, the Dog" series is her first attempt at writing for children. ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... annual Business Architecture Innovation Summit in Reston, VA on March 21-22, 2017. This ... share a range of experiences from a cross-section of industries such as financial ...
(Date:12/7/2016)... ... December 07, 2016 , ... NuevaCare, a leading home ... is proud to announce new city-specific pages as part of its ambitious website relaunch. ... they often look, first, for local agencies serving their city. The new site has ...
(Date:12/6/2016)... ... 06, 2016 , ... People with Parkinson’s disease and cognitive ... type of MRI, according to a study appearing online in the journal Radiology. ... characterized by tremors or trembling and stiffness in the limbs, impaired balance and ...
Breaking Medicine News(10 mins):